{"success":true,"data":{"pressRelease":{"id":"37591","rtpr_id":"nNFCbQfC5n","ticker":"BHST","exchange":"NASDAQ","all_tickers":["BHST"],"title":"Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation","author":"Newsfile Corp","published_at":"2026-05-18T11:00:18.750Z","article_body":"Expanded sweetener molecule development program aims to broaden access to\nplant-based sweetening solutions tailored to diverse customer food and\nbeverage categories.\n\nVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18,\n2026) - BioHarvest Sciences Inc.\n(https://api.newsfilecorp.com/redirect/anOZaSMNE2) (NASDAQ: BHST) (FSE: 8MV0),\na leader in Botanical Synthesis™ technology and sustainable plant-based\nmolecule development, today announced the expansion of its collaboration with\nTate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for\nhealthier food and beverages, broadening the scope of their joint sweetener\ndevelopment program to include multiple plant-based sweetener molecules.\n\nThe expanded collaboration builds on the initial agreement signed in 2024 and\nreflects strong technical progress to date, as well as Tate & Lyle's ambition\nto equip food and beverage manufacturers with a flexible toolkit of sweetening\nsolutions that can be tailored to different formulation needs.\n\nAs customer requirements around taste, cost and labelling continue to evolve,\nno single sweetener can address all food and beverage category needs. Tate &\nLyle's approach focuses on developing complementary sweetening options that\ncan be used independently or together - enabling product-specific optimisation\nwhile supporting sugar and calorie reduction goals.\n\nThe collaboration draws on BioHarvest's Botanical Synthesis™ platform, which\nsupports the development of plant-based, non-GMO ingredients, reducing the\nindustry's reliance on traditional agricultural extraction for rare or\nhard-to-source botanicals. This approach aligns with Tate & Lyle's focus on\ndelivering ingredient innovation that balances performance, scalability and\nresponsible sourcing considerations.\n\nThe partnership builds on Tate & Lyle's long-standing commitment to sugar and\ncalorie reduction and its track record in sweetener innovation. The company's\nheritage includes major industry milestones, from the discovery of sucralose\nin 1976, to the commercialisation at scale of allulose in 2015 and high-purity\nbioconverted stevia Reb M in 2018.\n\nToday, Tate & Lyle's development pipeline is focused on advancing sweetening\nsolutions that deliver great taste while supporting sugar and calorie\nreduction, helping customers meet evolving consumer expectations around health\nand wellbeing. This includes sweet ingredients that reduce sugar and calories\nand have the potential to support broader health and wellbeing needs.\n\nA 2025 proprietary Tate & Lyle survey across seven global markets found that\nover half of respondents planned to reduce their sugar consumption in the\nfollowing 12 months, with strong consumer interest in great-tasting sweeteners\nderived from fruits and plants([1]). The intent to reduce sugar was greater\nthan the intent to reduce calorie and fat consumption, showing how top of mind\nsugar reduction is for consumers.\n\nTate & Lyle's innovation approach is informed by more than a decade of global\nresearch into consumer perceptions of ingredients. This ensures that\nconsiderations such as sensory performance, value creation and label\nacceptance are embedded into ingredient development from the outset.\n\nVictoria Spadaro-Grant, Chief Science and Innovation Officer at Tate & Lyle,\nsaid:\n\n\"Expanding the scope of our collaboration with BioHarvest to include multiple\nplant-based sweetener molecules reflects the technical progress achieved to\ndate and the aim to further expand our broad toolbox of sweetening solutions.\nAs we define what customers ultimately look for in next-generation sweeteners\n- sugar-like taste, solutions anchored in nature, reduced calories and\nresponsible use of resources - it is clear that several unmet needs in the\nmarket today are unlikely to be addressed with a single sweetener.\n\n\"The flexibility from the expanded collaboration with BioHarvest is critical\nas customers seek food and beverage category-specific solutions that balance\ntaste, cost and labelling requirements, while supporting sugar and calorie\nreduction.\n\n\"This programme strengthens our innovation pipeline in a disciplined and\nefficient way and reinforces our commitment to advancing the future of\nsweetness through differentiated, science-led solutions.\"\n\nZaki Rakib, Chief Executive Officer of BioHarvest Sciences, added:\n\n\"Broadening the development program demonstrates confidence in the versatility\nof our Botanical Synthesis™ platform and in the progress delivered through\nour collaboration with Tate & Lyle. Together, we are enabling access to\ndifferentiated, plant-based sweetening solutions designed to support a range\nof sensory, application and economic requirements.\"\n\nFor media enquiries, contact: tateandlyle@citypress.co.uk\n\nAbout Tate & Lyle PLC:\n\nSupported by our 165-year history of ingredient innovation, we partner with\ncustomers to provide consumers with healthier and tastier choices when they\neat and drink. We are proud that millions of people around the world consume\nproducts containing our ingredients and solutions every day.\n\nThrough our leading expertise in sweetening, mouthfeel and fortification, we\ndevelop ingredients and solutions which reduce sugar, calories and fat, add\nfibre and protein, and provide texture and stability to food and drink in\ncategories including beverages, dairy, bakery, snacks, soups, sauces, and\ndressings.\n\nTate & Lyle recently acquired CP Kelco, a leading provider of pectin,\nspeciality gums and other nature-based ingredients to create a leader in\nmouthfeel, significantly enhancing our solutions capabilities. Following this\ncombination, we now have more than 5,000 employees working in around 75\nlocations in 38 countries, serving customers in more than 120 countries.\nScience, Solutions, Society is our brand promise and how we will achieve our\npurpose of Transforming Lives through the Science of Food. By living our\npurpose, we believe we can successfully grow our business and have a positive\nimpact on society. We live our purpose in three ways, by supporting healthy\nliving, building thriving communities and caring for our planet.\n\nTate & Lyle is listed on the London Stock Exchange under the symbol TATE.L.\nAmerican Depositary Receipts trade under TATYY. For the year ended 31 March\n2025, and on a pro forma basis which assumes for illustrative purposes that\nthe combination with CP Kelco took place on 1 April 2024, revenue for the\nenlarged Tate & Lyle Group would have been £2.12 billion. For more\ninformation, please visit www.tateandlyle.com or follow Tate & Lyle on\nLinkedIn, X (Twitter), Facebook or YouTube.\n\nAbout BioHarvest Sciences Inc:\n\nBioHarvest Sciences (NASDAQ: BHST) (FSE: 8MV) is an industrial plant cell\nculture company pioneering Botanical Synthesis™, a patented non-GMO platform\ntechnology that produces high-value, plant-derived compounds without growing\nthe plant itself. By combining proprietary plant cell biology, elicitation\ntechnologies, AI-driven development and industrial-scale bioreactors, the\nCompany creates \"precision botanics\" with enhanced potency, purity,\nconsistency and commercial scalability.\n\nBacked by more than $100 million invested in its technology platform, 15\npatents and multidisciplinary scientific capabilities, BioHarvest operates two\ncomplementary growth engines: a rapidly growing direct-to-consumer business\nand an expanding CDMO division serving pharmaceutical, nutraceutical,\ncosmetic, fragrance and nutrition markets. BioHarvest's platform has achieved\ncommercial validation through VINIA®, its flagship blood flow health product,\nwhich has generated nearly $100 million in cumulative sales. The Company's\nCDMO business is advancing multiple high-value development programs, including\nrare fragrance, novel sweetener, and saffron-derived compounds, while securing\nlong-term royalty participation opportunities through strategic partnerships.\n\nBioHarvest's proprietary Botanical Synthesis platform enables the sustainable\nproduction of scarce and highly valuable botanical compounds at industrial\nscale, positioning the Company at the forefront of next-generation plant-based\ninnovation. With a growing pipeline of commercial collaborations, expanding\nmanufacturing capabilities and increasing global industry interest, BioHarvest\nis establishing itself as a strategic innovation partner for companies seeking\ndifferentiated, science-driven botanical solutions.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements within the meaning of\napplicable securities laws. These statements are based on management's current\nexpectations, beliefs, and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially. For the\nCDMO Services Business Unit, there is no assurance of additional future\ncontracts, and readers are cautioned that increased revenue is not necessarily\nan increase in net income or profitability as costs will likely increase as\nwell. There is no assurance that signed research agreements will proceed past\na contracted stage, or that a developed molecule or compound will be\ncommercialized or will generate royalties to the Company. Successful\ncommercialization of any compound developed will be subject to consumer\npreferences, advertising budgets and other factors affecting market acceptance\nof new products which are uncertain and cannot be assured. Readers are\ncautioned not to place undue reliance on forward-looking statements. The\nCompany does not undertake any obligation to update forward-looking statements\nexcept as required by applicable law. Additional information is contained in\nthe Company's SEC filings, available at http://www.sec.gov.\n\nBioHarvest Company Contact:\n\nDave Ryan, VP Investor Relations\n(604) 622-1186\ninfo@bioharvest.com\n\nInvestor Relations Contact:\n\nChuck Padala, Managing Director\nLifeSci Advisors\nchuck@lifesciadvisors.com\n\n(1) Tate & Lyle Proprietary Ingredient Tracker Research - 2025 (Includes 7\nMarkets - US, Brazil, Germany, UK, UAE, China, and India; 1,000 respondents\nper market\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/297782","article_body_html":"","raw_payload":{"data":{"id":"nNFCbQfC5n","title":"Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation","author":"Newsfile Corp","ticker":"BHST","created":"2026-05-18T11:00:18.750Z","tickers":["BHST"],"exchange":"NASDAQ","article_body":"Expanded sweetener molecule development program aims to broaden access to\nplant-based sweetening solutions tailored to diverse customer food and\nbeverage categories.\n\nVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18,\n2026) - BioHarvest Sciences Inc.\n(https://api.newsfilecorp.com/redirect/anOZaSMNE2) (NASDAQ: BHST) (FSE: 8MV0),\na leader in Botanical Synthesis™ technology and sustainable plant-based\nmolecule development, today announced the expansion of its collaboration with\nTate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for\nhealthier food and beverages, broadening the scope of their joint sweetener\ndevelopment program to include multiple plant-based sweetener molecules.\n\nThe expanded collaboration builds on the initial agreement signed in 2024 and\nreflects strong technical progress to date, as well as Tate & Lyle's ambition\nto equip food and beverage manufacturers with a flexible toolkit of sweetening\nsolutions that can be tailored to different formulation needs.\n\nAs customer requirements around taste, cost and labelling continue to evolve,\nno single sweetener can address all food and beverage category needs. Tate &\nLyle's approach focuses on developing complementary sweetening options that\ncan be used independently or together - enabling product-specific optimisation\nwhile supporting sugar and calorie reduction goals.\n\nThe collaboration draws on BioHarvest's Botanical Synthesis™ platform, which\nsupports the development of plant-based, non-GMO ingredients, reducing the\nindustry's reliance on traditional agricultural extraction for rare or\nhard-to-source botanicals. This approach aligns with Tate & Lyle's focus on\ndelivering ingredient innovation that balances performance, scalability and\nresponsible sourcing considerations.\n\nThe partnership builds on Tate & Lyle's long-standing commitment to sugar and\ncalorie reduction and its track record in sweetener innovation. The company's\nheritage includes major industry milestones, from the discovery of sucralose\nin 1976, to the commercialisation at scale of allulose in 2015 and high-purity\nbioconverted stevia Reb M in 2018.\n\nToday, Tate & Lyle's development pipeline is focused on advancing sweetening\nsolutions that deliver great taste while supporting sugar and calorie\nreduction, helping customers meet evolving consumer expectations around health\nand wellbeing. This includes sweet ingredients that reduce sugar and calories\nand have the potential to support broader health and wellbeing needs.\n\nA 2025 proprietary Tate & Lyle survey across seven global markets found that\nover half of respondents planned to reduce their sugar consumption in the\nfollowing 12 months, with strong consumer interest in great-tasting sweeteners\nderived from fruits and plants([1]). The intent to reduce sugar was greater\nthan the intent to reduce calorie and fat consumption, showing how top of mind\nsugar reduction is for consumers.\n\nTate & Lyle's innovation approach is informed by more than a decade of global\nresearch into consumer perceptions of ingredients. This ensures that\nconsiderations such as sensory performance, value creation and label\nacceptance are embedded into ingredient development from the outset.\n\nVictoria Spadaro-Grant, Chief Science and Innovation Officer at Tate & Lyle,\nsaid:\n\n\"Expanding the scope of our collaboration with BioHarvest to include multiple\nplant-based sweetener molecules reflects the technical progress achieved to\ndate and the aim to further expand our broad toolbox of sweetening solutions.\nAs we define what customers ultimately look for in next-generation sweeteners\n- sugar-like taste, solutions anchored in nature, reduced calories and\nresponsible use of resources - it is clear that several unmet needs in the\nmarket today are unlikely to be addressed with a single sweetener.\n\n\"The flexibility from the expanded collaboration with BioHarvest is critical\nas customers seek food and beverage category-specific solutions that balance\ntaste, cost and labelling requirements, while supporting sugar and calorie\nreduction.\n\n\"This programme strengthens our innovation pipeline in a disciplined and\nefficient way and reinforces our commitment to advancing the future of\nsweetness through differentiated, science-led solutions.\"\n\nZaki Rakib, Chief Executive Officer of BioHarvest Sciences, added:\n\n\"Broadening the development program demonstrates confidence in the versatility\nof our Botanical Synthesis™ platform and in the progress delivered through\nour collaboration with Tate & Lyle. Together, we are enabling access to\ndifferentiated, plant-based sweetening solutions designed to support a range\nof sensory, application and economic requirements.\"\n\nFor media enquiries, contact: tateandlyle@citypress.co.uk\n\nAbout Tate & Lyle PLC:\n\nSupported by our 165-year history of ingredient innovation, we partner with\ncustomers to provide consumers with healthier and tastier choices when they\neat and drink. We are proud that millions of people around the world consume\nproducts containing our ingredients and solutions every day.\n\nThrough our leading expertise in sweetening, mouthfeel and fortification, we\ndevelop ingredients and solutions which reduce sugar, calories and fat, add\nfibre and protein, and provide texture and stability to food and drink in\ncategories including beverages, dairy, bakery, snacks, soups, sauces, and\ndressings.\n\nTate & Lyle recently acquired CP Kelco, a leading provider of pectin,\nspeciality gums and other nature-based ingredients to create a leader in\nmouthfeel, significantly enhancing our solutions capabilities. Following this\ncombination, we now have more than 5,000 employees working in around 75\nlocations in 38 countries, serving customers in more than 120 countries.\nScience, Solutions, Society is our brand promise and how we will achieve our\npurpose of Transforming Lives through the Science of Food. By living our\npurpose, we believe we can successfully grow our business and have a positive\nimpact on society. We live our purpose in three ways, by supporting healthy\nliving, building thriving communities and caring for our planet.\n\nTate & Lyle is listed on the London Stock Exchange under the symbol TATE.L.\nAmerican Depositary Receipts trade under TATYY. For the year ended 31 March\n2025, and on a pro forma basis which assumes for illustrative purposes that\nthe combination with CP Kelco took place on 1 April 2024, revenue for the\nenlarged Tate & Lyle Group would have been £2.12 billion. For more\ninformation, please visit www.tateandlyle.com or follow Tate & Lyle on\nLinkedIn, X (Twitter), Facebook or YouTube.\n\nAbout BioHarvest Sciences Inc:\n\nBioHarvest Sciences (NASDAQ: BHST) (FSE: 8MV) is an industrial plant cell\nculture company pioneering Botanical Synthesis™, a patented non-GMO platform\ntechnology that produces high-value, plant-derived compounds without growing\nthe plant itself. By combining proprietary plant cell biology, elicitation\ntechnologies, AI-driven development and industrial-scale bioreactors, the\nCompany creates \"precision botanics\" with enhanced potency, purity,\nconsistency and commercial scalability.\n\nBacked by more than $100 million invested in its technology platform, 15\npatents and multidisciplinary scientific capabilities, BioHarvest operates two\ncomplementary growth engines: a rapidly growing direct-to-consumer business\nand an expanding CDMO division serving pharmaceutical, nutraceutical,\ncosmetic, fragrance and nutrition markets. BioHarvest's platform has achieved\ncommercial validation through VINIA®, its flagship blood flow health product,\nwhich has generated nearly $100 million in cumulative sales. The Company's\nCDMO business is advancing multiple high-value development programs, including\nrare fragrance, novel sweetener, and saffron-derived compounds, while securing\nlong-term royalty participation opportunities through strategic partnerships.\n\nBioHarvest's proprietary Botanical Synthesis platform enables the sustainable\nproduction of scarce and highly valuable botanical compounds at industrial\nscale, positioning the Company at the forefront of next-generation plant-based\ninnovation. With a growing pipeline of commercial collaborations, expanding\nmanufacturing capabilities and increasing global industry interest, BioHarvest\nis establishing itself as a strategic innovation partner for companies seeking\ndifferentiated, science-driven botanical solutions.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements within the meaning of\napplicable securities laws. These statements are based on management's current\nexpectations, beliefs, and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially. For the\nCDMO Services Business Unit, there is no assurance of additional future\ncontracts, and readers are cautioned that increased revenue is not necessarily\nan increase in net income or profitability as costs will likely increase as\nwell. There is no assurance that signed research agreements will proceed past\na contracted stage, or that a developed molecule or compound will be\ncommercialized or will generate royalties to the Company. Successful\ncommercialization of any compound developed will be subject to consumer\npreferences, advertising budgets and other factors affecting market acceptance\nof new products which are uncertain and cannot be assured. Readers are\ncautioned not to place undue reliance on forward-looking statements. The\nCompany does not undertake any obligation to update forward-looking statements\nexcept as required by applicable law. Additional information is contained in\nthe Company's SEC filings, available at http://www.sec.gov.\n\nBioHarvest Company Contact:\n\nDave Ryan, VP Investor Relations\n(604) 622-1186\ninfo@bioharvest.com\n\nInvestor Relations Contact:\n\nChuck Padala, Managing Director\nLifeSci Advisors\nchuck@lifesciadvisors.com\n\n(1) Tate & Lyle Proprietary Ingredient Tracker Research - 2025 (Includes 7\nMarkets - US, Brazil, Germany, UK, UAE, China, and India; 1,000 respondents\nper market\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/297782"},"type":"article","timestamp":"2026-05-18T11:00:18.789529001Z","server_sent_at_ms":1779102018789},"received_at":"2026-05-18T11:00:18.848Z","source_url":"https://www.newsfilecorp.com/release/297782"},"analysis":{"id":"27035","press_release_id":"37591","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Forward-looking statements caution that signed research agreements may not proceed past contracted stage or generate royalties","No assurance of commercialization or profitability from CDMO contracts"],"eventType":"partnership","narrative":"BioHarvest Sciences expanded its collaboration with Tate & Lyle to develop multiple plant-based sweetener molecules, broadening the scope of their initial 2024 agreement.\n\nThe partnership leverages BioHarvest’s proprietary Botanical Synthesis™ platform to create non-GMO, plant-derived ingredients, addressing Tate & Lyle’s need for a flexible toolkit of sweetening solutions.\n\nThis move validates BioHarvest’s CDMO capabilities and diversifies its revenue streams beyond its direct-to-consumer flagship product, VINIA®, which has generated nearly $100 million in cumulative sales.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"BioHarvest secures major platform validation with Tate & Lyle expansion, signaling growth in its CDMO division."},"keyFigures":{"customDimensions":{"platform_investment":"$100 million","vinia_cumulative_sales":"$100 million","tate_lyle_pro_forma_revenue":"£2.12 billion"}},"quotedText":"Broadening the development program demonstrates confidence in the versatility of our Botanical Synthesis™ platform and in the progress delivered through our collaboration with Tate & Lyle.","namedEntities":{"people":[{"name":"Victoria Spadaro-Grant","role":"Chief Science and Innovation Officer at Tate & Lyle"},{"name":"Zaki Rakib","role":"Chief Executive Officer of BioHarvest Sciences"},{"name":"Dave Ryan","role":"VP Investor Relations"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors"}],"products":["Botanical Synthesis™","VINIA®","sucralose","allulose","stevia Reb M"],"companies":[{"name":"BioHarvest Sciences Inc.","ticker":"BHST","relationship":"filer"},{"name":"Tate & Lyle PLC","ticker":"TATE.L","relationship":"partner"},{"name":"CP Kelco","relationship":"subsidiary/acquired entity of partner"},{"name":"LifeSci Advisors","relationship":"investor relations advisor"}],"dollarAmounts":[{"amount":"$100 million","context":"investment in BioHarvest technology platform"},{"amount":"$100 million","context":"cumulative sales of VINIA®"},{"amount":"£2.12 billion","context":"pro forma revenue for Tate & Lyle Group"}]},"materialImpact":{"score":3,"reasoning":"Expansion of a strategic CDMO collaboration with a major global ingredient player (Tate & Lyle) validates BioHarvest's proprietary Botanical Synthesis platform and diversifies its pipeline beyond its direct-to-consumer business. While no immediate revenue is guaranteed, it represents significant commercial progress for a pre-profit biotech."},"tickerRelevance":{"others":[{"ticker":"TATE.L","relevance":"partner"},{"ticker":"TATYY","relevance":"partner ADR"}],"primary":"BHST"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strategic_partnership_expansion","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"BioHarvest Sciences expanded its collaboration with Tate & Lyle to develop multiple plant-based sweetener molecules, broadening the scope of their initial 2024 agreement.\n\nThe partnership leverages BioHarvest’s proprietary Botanical Synthesis™ platform to create non-GMO, plant-derived ingredients, addressing Tate & Lyle’s need for a flexible toolkit of sweetening solutions.\n\nThis move validates BioHarvest’s CDMO capabilities and diversifies its revenue streams beyond its direct-to-consumer flagship product, VINIA®, which has generated nearly $100 million in cumulative sales.","key_figures":{"customDimensions":{"platform_investment":"$100 million","vinia_cumulative_sales":"$100 million","tate_lyle_pro_forma_revenue":"£2.12 billion"}},"named_entities":{"people":[{"name":"Victoria Spadaro-Grant","role":"Chief Science and Innovation Officer at Tate & Lyle"},{"name":"Zaki Rakib","role":"Chief Executive Officer of BioHarvest Sciences"},{"name":"Dave Ryan","role":"VP Investor Relations"},{"name":"Chuck Padala","role":"Managing Director, LifeSci Advisors"}],"products":["Botanical Synthesis™","VINIA®","sucralose","allulose","stevia Reb M"],"companies":[{"name":"BioHarvest Sciences Inc.","ticker":"BHST","relationship":"filer"},{"name":"Tate & Lyle PLC","ticker":"TATE.L","relationship":"partner"},{"name":"CP Kelco","relationship":"subsidiary/acquired entity of partner"},{"name":"LifeSci Advisors","relationship":"investor relations advisor"}],"dollarAmounts":[{"amount":"$100 million","context":"investment in BioHarvest technology platform"},{"amount":"$100 million","context":"cumulative sales of VINIA®"},{"amount":"£2.12 billion","context":"pro forma revenue for Tate & Lyle Group"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T11:05:59.093Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"strategic_partnership_expansion","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral"}},"durationMs":25703,"modelName":"george-droid-qwen-72b"}}